EUVIMEDEUVIMED entdecken
Crossref

Bioinformatics‐Based Exploration of LMO4 ‐Regulated Hippo Pathway to Reverse Adriamycin Resistance in Breast Cancer

Yue Wu, Jiahui Gao, Zejie Su, Anran Gao, Jingxiu Zhao, Guanying Qiao, Minling Ye, Dongdong Liu, Jianhua Xu iD

IUBMB Life · 2025

DOI: 10.1002/iub.70033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IUBMB Life, 2025. Verfasst von Yue Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Shunde Hospital of Guangzhou University of Chinese Medicine, Foshan, China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Doxorubicin, Breast Neoplasms, Adaptor Proteins, Signal Transducing. Die Arbeit nennt 53 Literaturangaben. Gefördert von: The Shunde Hospital of Guangzhou University of Traditional Chinese Medicine, The Guangdong Provincial Medical Science and Technology Research Fund Project, The Medical Research Project of Foshan Health Bureau in 2023.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of acquired drug resistance in breast cancer (BC) significantly compromises treatment efficacy and patient survival, yet the underlying molecular mechanisms remain completely understood. In this study, we investigated the role of the Hippo signaling pathway and its regulatory factor, LIM Domain Only 4 (LMO4), in the acquired Adriamycin (ADR)‐resistant MCF‐7 (AdrR) cells. Using a combination of bioinformatics and experimental approaches, we demonstrated that AdrR cells exhibit defective apoptosis upon ADR treatment, characterized by abnormal expression of apoptotic proteins such as BAX and BCL2. RNA sequencing (RNA‐seq) and ATAC sequencing (ATAC‐seq) revealed significant dysregulation of the Hippo pathway in AdrR cells compared to parental MCF‐7 cells, suggesting its involvement in mediating drug resistance. Further experiments showed that small interfering RNA (siRNA)‐mediated knockdown of LMO4 (siLMO4) altered the expression of apoptotic proteins and partially restored ADR sensitivity in AdrR cells. Mechanistically, LMO4 was found to modulate the Hippo pathway, as evidenced by changes in the nuclear translocation of YAP and the phosphorylation levels of key Hippo pathway components (MST1/2 and YAP). Inhibition of the Hippo pathway using a Lats kinase inhibitor further confirmed its role in regulating drug resistance. Our findings highlight the critical involvement of the LMO4‐Hippo signaling axis in ADR resistance and propose LMO4 as a potential therapeutic target for reversing chemoresistance in BC. This study provides novel insights into the molecular mechanisms of drug resistance and offers a foundation for future research aimed at improving treatment strategies for ADR‐resistant breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmDoxorubicinBreast NeoplasmsAdaptor Proteins, Signal TransducingProtein Serine-Threonine KinasesLIM Domain ProteinsHumansHippo Signaling PathwayFemaleComputational BiologyGene Expression Regulation, NeoplasticSignal TransductionApoptosisMCF-7 CellsAntibiotics, Antineoplastic

Stichwörter der Autor:innen

LMO4adriamycin (ADR)‐resistantapoptosisbreast cancer (BC)drug sensitivityhippo signaling pathway

Substanzen

DoxorubicinAdaptor Proteins, Signal TransducingProtein Serine-Threonine KinasesLIM Domain ProteinsLMO4 protein, humanAntibiotics, Antineoplastic

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Shunde Hospital of Guangzhou University of Chinese Medicine, Foshan, China.
  • Department of Clinical Laboratory, Hongdu Hospital of Traditional Chinese Medicine, Nanchang, China.
  • Department of Translational Medicine Research Center and Pharmacy, Shunde Hospital of Guangzhou University of Chinese Medicine, Foshan, China.
  • Department of Cancer Laboratory, Shunde Hospital of Guangzhou University of Chinese Medicine, Foshan, China.
  • Department of Laboratory Science, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.
  • Department of Clinical Laboratory, Maoming Hospital of Guangzhou University of Chinese Medicine, Maoming, China.

ORCID-Profile: Jianhua Xu

Förderung

  • The Shunde Hospital of Guangzhou University of Traditional Chinese Medicine
  • The Guangdong Provincial Medical Science and Technology Research Fund Project
  • The Medical Research Project of Foshan Health Bureau in 2023
  • The Research Projects of Guangdong Provincial Administration of Traditional Chinese Medicine
  • The Science and Technology Innovation Project of Maoming Municipality

Zitieren

APA

Wu, Y., Gao, J., Su, Z., Gao, A., Zhao, J., Qiao, G., Ye, M., Liu, D., & Xu, J. (2025). Bioinformatics‐Based Exploration of LMO4 ‐Regulated Hippo Pathway to Reverse Adriamycin Resistance in Breast Cancer. IUBMB Life. https://doi.org/10.1002/iub.70033

Vancouver

Wu Y, Gao J, Su Z, Gao A, Zhao J, Qiao G, et al. Bioinformatics‐Based Exploration of LMO4 ‐Regulated Hippo Pathway to Reverse Adriamycin Resistance in Breast Cancer. IUBMB Life. 2025. doi:10.1002/iub.70033

BibTeX
@article{Wu2025,
  author = {Wu, Yue and Gao, Jiahui and Su, Zejie and Gao, Anran and Zhao, Jingxiu and Qiao, Guanying and Ye, Minling and Liu, Dongdong and Xu, Jianhua},
  title = {Bioinformatics‐Based Exploration of LMO4 ‐Regulated Hippo Pathway to Reverse Adriamycin Resistance in Breast Cancer},
  journal = {IUBMB Life},
  year = {2025},
  doi = {10.1002/iub.70033}
}
Kostenlos starten →